{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T04:35:50Z","timestamp":1762662950247,"version":"build-2065373602"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals\u2019 Ascent Plan","doi-asserted-by":"crossref","award":["DFL20221402"],"award-info":[{"award-number":["DFL20221402"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a major global health threat, underscoring the urgent need for novel therapeutics. 5-Iodotubercidin (5-ITu), a purine-based protein kinase inhibitor, has not been previously evaluated for anti-tuberculosis (anti-TB) applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study presents the first comprehensive characterization of 5-ITu as a lead compound for TB treatment, focusing on its antimicrobial activity, pharmacokinetic (PK) properties and safety profile. 5-ITu exhibited notable antimicrobial activity against Mycobacterium tuberculosis (MTB) standard strain H37Rv and 25 multidrug-resistant (MDR) clinical isolates, with MIC values ranging from 0.23 to 0.9\u00a0\u03bcg ml\u22121, while showing MIC values &amp;gt;32\u00a0\u03bcg ml\u22121 against eight other bacterial strains. Checkerboard assays revealed synergy with multiple anti-TB drugs against clinical MDR isolates. The permeabilizing effect of 5-ITu on the bacterial inner membrane, along with the associated dissipation of membrane potential and reduction of intracellular ATP, was confirmed by membrane integrity and function assays. PK study in mice following oral administration of 10\u00a0mg kg\u22121 showed rapid absorption, high plasma exposure, and an atypical plateau during the elimination phase. Cytotoxicity assays and acute toxicity studies in mice revealed moderate toxicity of 5-ITu toward mammalian cells and rodents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite its moderate toxicity, the promising anti-TB activity and favorable PK profile of 5-ITu support its potential as a lead compound for structural optimization in anti-TB drug development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jambio\/lxaf257","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:10:17Z","timestamp":1760530217000},"source":"Crossref","is-referenced-by-count":0,"title":["5-Iodotubercidin: a novel anti-tuberculosis lead with promising antimicrobial activity, pharmacokinetics, and safety profile"],"prefix":"10.1093","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9229-0804","authenticated-orcid":false,"given":"Xuelin","family":"Wang","sequence":"first","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manyi","family":"Xu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyue","family":"Jia","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangxue","family":"Ye","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zimo","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eryue","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Department of Pharmacology, , Beijing 101149 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025110823313451600_bib1","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/microorganisms10071299","article-title":"Analogues of pyrimidine nucleosides as mycobacteria growth inhibitors","volume":"10","author":"Alexandrova","year":"2022","journal-title":"Microorganisms"},{"key":"2025110823313451600_bib2","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025110823313451600_bib3","doi-asserted-by":"publisher","first-page":"114321","DOI":"10.1016\/j.bcp.2020.114321","article-title":"Adenosine kinase: a key regulator of purinergic physiology","volume":"187","author":"Boison","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"2025110823313451600_bib4","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1074\/jbc.RA118.006761","article-title":"5'-Iodotubercidin represses insulinoma associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth","volume":"294","author":"Chen","year":"2019","journal-title":"J Biol Chem"},{"key":"2025110823313451600_bib5","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1021\/acs.jmedchem.9b00020","article-title":"Structure-guided drug design of 6-substituted adenosine analogues as potent inhibitors of Mycobacterium tuberculosis adenosine kinase","volume":"62","author":"Crespo","year":"2019","journal-title":"J Med Chem"},{"key":"2025110823313451600_bib6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/acsmedchemlett.8b00090","article-title":"Conformationally constrained cinnolinone nucleoside analogues as siderophore biosynthesis inhibitors for tuberculosis","volume":"9","author":"Dawadi","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"2025110823313451600_bib7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4155\/fmc.14.166","article-title":"Nucleoside analogs and tuberculosis: new weapons against an old enemy","volume":"7","author":"Ferrari","year":"2015","journal-title":"Future Med Chem"},{"key":"2025110823313451600_bib8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0167-4889(95)00196-4","article-title":"5-Iodotubercidin and proglycosyn: a comparison of two glycogenic compounds in hepatocytes from fasted rats","volume":"1311","author":"Fl\u00fcckiger-Isler","year":"1996","journal-title":"Mole Cell Res"},{"key":"2025110823313451600_bib9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1042\/bj2920085","article-title":"Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin","volume":"292","author":"Fl\u00fcckiger-Isler","year":"1993","journal-title":"Biochem J"},{"key":"2025110823313451600_bib10","doi-asserted-by":"publisher","first-page":"e2426827122","DOI":"10.1073\/pnas.2426827122","article-title":"Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity","volume":"122","author":"Fountain","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"2025110823313451600_bib11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2025110823313451600_bib12","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"2025110823313451600_bib13","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.6023\/cjoc201402027","article-title":"An improved total synthesis of tubercidin","volume":"34","author":"Huang","year":"2014","journal-title":"Chin J Org Chem"},{"key":"2025110823313451600_bib14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejmech.2018.07.062","article-title":"Synthesis of a 3'-C-ethynyl-\u03b2-d-ribofuranose purine nucleoside library: discovery of C7-deazapurine analogs as potent antiproliferative nucleosides","volume":"157","author":"Hulpia","year":"2018","journal-title":"Eur J Med Chem"},{"key":"2025110823313451600_bib15","doi-asserted-by":"publisher","first-page":"e00506","DOI":"10.1002\/prp2.506","article-title":"Therapeutic potential of adenosine kinase inhibition-revisited","volume":"7","author":"Jarvis","year":"2019","journal-title":"Pharmacol Res Perspec"},{"key":"2025110823313451600_bib16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.bbrc.2017.07.008","article-title":"Inhibitory effect of 5-iodotubercidin on pigmentation","volume":"490","author":"Kim","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2025110823313451600_bib17","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/antibiotics12091418","article-title":"Utilization of existing human kinase inhibitors as scaffolds in the development of new antimicrobials","volume":"12","author":"Konaklieva","year":"2023","journal-title":"Antibiotics"},{"key":"2025110823313451600_bib18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.apsb.2025.01.023","article-title":"Revolutionizing tuberculosis treatment: breakthroughs, challenges, and hope on the horizon","volume":"15","author":"Kufa","year":"2025","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2025110823313451600_bib19","doi-asserted-by":"publisher","first-page":"914188","DOI":"10.3389\/fphar.2022.914188","article-title":"Isobavachalcone from Cullen corylifolium Presents Significant Antibacterial Activity Against Clostridium difficile through Disruption of the Cell Membrane","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025110823313451600_bib20","doi-asserted-by":"publisher","first-page":"1902227","DOI":"10.1002\/advs.201902227","article-title":"Metformin restores tetracyclines susceptibility against multidrug resistant bacteria","volume":"7","author":"Liu","year":"2020","journal-title":"Adv Sci"},{"key":"2025110823313451600_bib21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejmech.2019.05.081","article-title":"Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines","volume":"178","author":"Maslov","year":"2019","journal-title":"Eur J Med Chem"},{"key":"2025110823313451600_bib22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1042\/bj2990123","article-title":"Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor","volume":"299","author":"Massillon","year":"1994","journal-title":"Biochem J"},{"key":"2025110823313451600_bib23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","article-title":"Recent advances in the treatment of tuberculosis","volume":"30","author":"Motta","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2025110823313451600_bib24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1021\/jm4018948","article-title":"Synthesis, cytostatic, antimicrobial, and anti-HCV activity of 6-substituted 7-(het)aryl-7-deazapurine ribonucleosides","volume":"57","author":"Nau\u0161","year":"2014","journal-title":"J Med Chem"},{"key":"2025110823313451600_bib25","doi-asserted-by":"publisher","first-page":"e70033","DOI":"10.1002\/jimd.70033","article-title":"Adenosine kinase: an epigenetic modulator and drug target","volume":"48","author":"Peter-Okaka","year":"2025","journal-title":"J of Inher Metab Disea"},{"key":"2025110823313451600_bib26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0378-4347(85)80193-6","article-title":"Analytical strategies for therapeutic monitoring of drugs in biological fluids","volume":"340","author":"Silva","year":"1985","journal-title":"J Chromatogr B:Biomed Sci Appl"},{"key":"2025110823313451600_bib27","doi-asserted-by":"publisher","first-page":"103955","DOI":"10.1016\/j.drudis.2024.103955","article-title":"Tuberculosis treatment-shortening","volume":"29","author":"Singh","year":"2024","journal-title":"Drug Discovery Today"},{"key":"2025110823313451600_bib28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1128\/CMR.16.3.463-496.2003","article-title":"Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence","volume":"16","author":"Smith","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"2025110823313451600_bib29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41564-020-0723-z","article-title":"A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens","volume":"5","author":"Song","year":"2020","journal-title":"Nat Microbiol"},{"key":"2025110823313451600_bib30","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","article-title":"Clofazimine for the treatment of tuberculosis","volume":"14","author":"Stadler","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025110823313451600_bib31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/pharmaceutics16081049","article-title":"Assessment of the efficacy of the antihistamine drug rupatadine used alone or in combination against mycobacteria","volume":"16","author":"Tian","year":"2024","journal-title":"Pharmaceutics"},{"key":"2025110823313451600_bib32","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1021\/acs.jmedchem.6b00689","article-title":"South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase","volume":"59","author":"Toti","year":"2016","journal-title":"J Med Chem"},{"key":"2025110823313451600_bib33","doi-asserted-by":"publisher","first-page":"474 E471","DOI":"10.1016\/j.ajog.2024.12.008","article-title":"A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75\u00a0mg v 150\u00a0mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy","volume":"232","author":"Vinogradov","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"2025110823313451600_bib34","first-page":"1024","article-title":"Activities of 5-iodotubercidin against pathogenic fungi and its mode of actions","volume":"57","author":"Wei","year":"2022","journal-title":"Acta Pharmaceutica Sinica"},{"journal-title":"Global Tuberculosis Report","year":"2024","author":"World Health Organization","key":"2025110823313451600_bib35"},{"key":"2025110823313451600_bib36","doi-asserted-by":"publisher","first-page":"e02155","DOI":"10.1128\/AAC.02155-18","article-title":"In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110823313451600_bib37","doi-asserted-by":"publisher","first-page":"112873","DOI":"10.1016\/j.biopha.2022.112873","article-title":"Synergistic antibacterial activity of tetrandrine combined with colistin against MCR-mediated colistin-resistant Salmonella","volume":"149","author":"Yi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025110823313451600_bib38","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1021\/acs.jmedchem.0c01720","article-title":"Intestinal excretion, intestinal recirculation, and renal tubule reabsorption are underappreciated mechanisms that drive the distribution and pharmacokinetic behavior of small molecule drugs","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"2025110823313451600_bib39","doi-asserted-by":"publisher","first-page":"e62527","DOI":"10.1371\/journal.pone.0062527","article-title":"Identification of 5-iodotubercidin as a genotoxic drug with anti-cancer potential","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"2025110823313451600_bib40","doi-asserted-by":"publisher","first-page":"105254","DOI":"10.1016\/j.antiviral.2022.105254","article-title":"5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis","volume":"198","author":"Zhao","year":"2022","journal-title":"Antiviral Res"},{"key":"2025110823313451600_bib41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1159\/000529616","article-title":"5-Iodotubercidin inhibits the growth of insulinoma cells by inducing apoptosis","volume":"113","author":"Zheng","year":"2023","journal-title":"Neuroendocrinology"},{"key":"2025110823313451600_bib42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/postmj\/qgad140","article-title":"Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis","volume":"100","author":"Zhong","year":"2024","journal-title":"Postgrad Med J"}],"container-title":["Journal of Applied Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jambio\/advance-article-pdf\/doi\/10.1093\/jambio\/lxaf257\/64711510\/lxaf257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jambio\/article-pdf\/136\/11\/lxaf257\/64711510\/lxaf257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jambio\/article-pdf\/136\/11\/lxaf257\/64711510\/lxaf257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T04:31:37Z","timestamp":1762662697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jambio\/article\/doi\/10.1093\/jambio\/lxaf257\/8286914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jambio\/lxaf257","relation":{},"ISSN":["1365-2672"],"issn-type":[{"type":"electronic","value":"1365-2672"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,15]]},"article-number":"lxaf257"}}